June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Response and dependence to ranibizumab therapy in AMD
Masako Kuroda; Hiroshi Kojima; Takanori Kameda; Michiko Mandai; Noriko Miyamoto; Akihiro Nishida; Yasuo Kurimoto
Author Affiliations & Notes
  • Masako Kuroda
    Kobe City Medical Center General Hospital, Kobe, Japan
    Institute of Biomedical Research and Innovation Hospital, Kobe, Japan
  • Hiroshi Kojima
    Kobe City Medical Center General Hospital, Kobe, Japan
    Institute of Biomedical Research and Innovation Hospital, Kobe, Japan
  • Takanori Kameda
    Kobe City Medical Center General Hospital, Kobe, Japan
    Institute of Biomedical Research and Innovation Hospital, Kobe, Japan
  • Michiko Mandai
    Kobe City Medical Center General Hospital, Kobe, Japan
    Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Kobe, Japan
  • Noriko Miyamoto
    Kobe City Medical Center General Hospital, Kobe, Japan
    Institute of Biomedical Research and Innovation Hospital, Kobe, Japan
  • Akihiro Nishida
    Kobe City Medical Center General Hospital, Kobe, Japan
    Institute of Biomedical Research and Innovation Hospital, Kobe, Japan
  • Yasuo Kurimoto
    Kobe City Medical Center General Hospital, Kobe, Japan
    Institute of Biomedical Research and Innovation Hospital, Kobe, Japan
  • Footnotes
    Commercial Relationships Masako Kuroda, None; Hiroshi Kojima, None; Takanori Kameda, None; Michiko Mandai, None; Noriko Miyamoto, None; Akihiro Nishida, None; Yasuo Kurimoto, HOYA (F), Santen (F), Senju (F), Abott (F), Alcon (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3805. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Response and dependence to ranibizumab therapy in AMD
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Masako Kuroda, Hiroshi Kojima, Takanori Kameda, Michiko Mandai, Noriko Miyamoto, Akihiro Nishida, Yasuo Kurimoto; Response and dependence to ranibizumab therapy in AMD. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3805.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: Immediate practice of as-needed injection of ranibizumab is still a burden to some patients or facility. To estimate a situation of therapy requirement, we aim to evaluate the response and dependency to ranibizumab injection therapy and related factors in neovascular age-related macular degeneration (AMD).

Methods: Medical records of 81 treatment-naïve AMD eyes of 80 Japanese patients who received initial three monthly intravitreal ranibizumab induction therapy in our clinic from Jun 2009 to Dec 2011 were reviewed. One month after completion of induction therapy, all eyes were evaluated and classified into two groups: well responded group if they did not need additional ranibizumab injection according to the PrONTO study protocol (AJO2009:148; 43-58), and insufficiently-responded group if they did. If the exudative change in OCT worsened within three months after completion of induction therapy, the eye was defined as treatment dependent. We thereby defined each subgroup as follows: group A; well-responded and non-dependent, group B; well-responded but dependent, group C; insufficiently-responded and non-dependent, and group D; insufficiently-responded and dependent.

Results: Forty-eight eyes (59%) well responded to the induction therapy whereas 33 eyes (41%) had insufficient response. The eyes in insufficiently-responded group had had a higher rate of cystoid macular edema (CME) (P < 0.01) and larger great linear dimension (GLD) (P < 0.05) before induction therapy. They did not show a significant improvement in visual acuity after induction therapy. Twenty-three eyes were categorized as group A, 25 as B, 15 as C and 18 as D. Eyes in group A needed less additional injections than those in group B, and showed a better visual outcome. Eyes in group D needed more injections than those in group C.

Conclusions: Of all treatment-naïve AMD patients, 59% well-responded to ranibizumab induction therapy. Half of these eyes were ranibizumab-dependent requiring repeated injections and showed poorer visual outcome. Insufficiently-responded eyes with CME or large GLD may require continuous re-injections or a combined therapy such as with photodynamic therapy.

Keywords: 412 age-related macular degeneration • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 585 macula/fovea  
© 2013, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept